SCHEMBL5370264

SCHEMBL5370264

CN(CCc1cccnc1)S(=O)(=O)c1csc2c1CCC/C2=N\O

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 1/20 0.39
TBXAS1 P24557 3/20 0.38
ALDH1A1 P00352 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
TDP1 Q9NUW8 1/20 0.34
HSD17B10 Q99714 1/20 0.33
TSHR P16473 1/20 0.32
USP2 O75604 1/20 0.32
MAPT P10636 1/20 0.32
DHPS P49366 1/20 0.32
TBXA2R P21731 1/20 0.31
FLT3 P36888 1/20 0.31
GAA P10253 1/20 0.31
RIPK1 Q13546 1/20 0.31
HTR2C P28335 1/20 0.31
NAMPT P43490 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5353957 1.00 CHRNA7 (0.39) CHRNA7TBXAS1ALDH1A1MEN1KMT2A
SCHEMBL5356166 0.89 KMT2A (0.32) KMT2ANAMPT
SCHEMBL5356170 0.89 KMT2A (0.32) KMT2ANAMPT
SCHEMBL5360242 0.87 CHRNA7 (0.41) CHRNA7TBXAS1ALDH1A1MEN1KMT2A
SCHEMBL5356580 0.83 TAAR1 (0.34) MAPT
SCHEMBL5355810 0.76
SCHEMBL5352985 0.74 KMT2A (0.32) MEN1KMT2AHSD17B10NAMPT
SCHEMBL5368093 0.73 ALDH1A1 (0.32) ALDH1A1MEN1KMT2AMAPTFLT3
SCHEMBL5358825 0.70 AOC3 (0.37)
SCHEMBL5353876 0.70 AOC3 (0.37)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7217723-B2 Substituted benzothiophenes, e.g., 7Z)-7-hydroxyimino-4,5,6,7-tetrahydro-benzo[b]thiophene-3-sulfonic acid [2-(4-fluorophenyl)-2-hydroxyethyl]-methyl-amide; treating allergies such as atopic dermatitis, allergic coryza, bronchial asthma, hypersensitive pneumoniac and pulmonary aspergillosis. EISAI CO., LTD. (JP) 2007-05-15 US disclosed
US-20050227959-A1 Heterocyclic compound having oxime group EISAI CO., LTD. (JP) 2005-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227959-A1 Heterocyclic compound having oxime group STAT6, HRH4, HRH2 CHRNA7 2377/4885TBXAS1 419/4885ALDH1A1 1391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.